332 related articles for article (PubMed ID: 26981529)
1. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Liu Q; Wang C; Li P; Liu J; Huang G; Song S
Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
4. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
Lin CY; Lin CL; Kao CH
Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
[TBL] [Abstract][Full Text] [Related]
5. Integrated
Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
[TBL] [Abstract][Full Text] [Related]
6. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
Li H; Yao L; Jin P; Hu L; Li X; Guo T; Yang K
Breast; 2018 Aug; 40():106-115. PubMed ID: 29758503
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis.
Yin Y; Liu X; Yang X; Guo J; Wang Q; Chen L
Spine J; 2018 Dec; 18(12):2323-2332. PubMed ID: 30121323
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
Pahk K; Kim S; Choe JG
Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
[TBL] [Abstract][Full Text] [Related]
9. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
Xiao Y; Wang L; Jiang X; She W; He L; Hu G
Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
[TBL] [Abstract][Full Text] [Related]
14. The accuracy of
Tian F; Shen G; Deng Y; Diao W; Jia Z
Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
[TBL] [Abstract][Full Text] [Related]
15. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.
Huang X; Yang J; Li J; Xiong Y
Medicine (Baltimore); 2020 Aug; 99(35):e20932. PubMed ID: 32871859
[TBL] [Abstract][Full Text] [Related]
16. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
Li YL; Wu LM; Chen XX; Delproposto Z; Hu JN; Xu JR
J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
18. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer.
Park SH; Moon WK; Cho N; Chang JM; Im SA; Park IA; Kang KW; Han W; Noh DY
Eur Radiol; 2012 Jan; 22(1):18-25. PubMed ID: 21845462
[TBL] [Abstract][Full Text] [Related]
19. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
20. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
